Development of the mRNA Therapeutic—Not Warp Speed!

This presentation will summarize the state-of-the-art in transporters in drug development based on four recent ITC3 whitepapers (Clin Pharmacol Ther 104, October 2018). Practical overview of emerging transporters of clinical relevance will be provided (e.g., OCT1, OATP2B1, etc.). Best practice in design of clinical DDI studies will be illustrated with recent advances in the study of OCT1, P-gp, and BCRP. Considerations for optimal selection of clinical probe drugs, including future potential utility of transporter biomarkers, also will be discussed.

The benefits of multiplex immunohistochemistry assays for tissue analysis are numerous. High-level multiplexing, whole slide imaging, workflow compatibility, and spatial analysis are all must-have requirements for effective multiplex IHC solutions. This webinar will provide insight into how Ultivue’s InSituPlex® technology addresses each of these needs and current challenges to enable researchers to unmask the true biology of tissue samples.

At the conclusion of this course, participants will be able to apply the following: Define terms such as biological agent, bioterrorism and bioterrorism attack.

Understanding the underlying biological processes in human health and disease requires studies integrating data from genomic, epigenomic, transcriptomic, proteomic, and metabolomic experiments.